
## Peter W F Wilson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5102346/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation, 1998, 97, 1837-1847.	1.6	8,099
2	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation, 2014, 129, S1-45.	1.6	4,842
3	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation, 2014, 129, S49-73.	1.6	2,823
4	Forecasting the Future of Cardiovascular Disease in the United States. Circulation, 2011, 123, 933-944.	1.6	2,690
5	Cardiovascular disease risk profiles. American Heart Journal, 1991, 121, 293-298.	1.2	1,900
6	Validation of the Framingham Coronary Heart Disease Prediction Scores. JAMA - Journal of the American Medical Association, 2001, 286, 180.	3.8	1,798
7	Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. Circulation, 2005, 112, 3066-3072.	1.6	1,650
8	Overweight and Obesity as Determinants of Cardiovascular Risk. Archives of Internal Medicine, 2002, 162, 1867.	4.3	1,550
9	Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature Genetics, 2018, 50, 1412-1425.	9.4	924
10	Impact of Obesity on Plasma Natriuretic Peptide Levels. Circulation, 2004, 109, 594-600.	1.6	856
11	Prediction of Incident Diabetes Mellitus in Middle-aged Adults. Archives of Internal Medicine, 2007, 167, 1068.	4.3	798
12	Genotype Score in Addition to Common Risk Factors for Prediction of Type 2 Diabetes. New England Journal of Medicine, 2008, 359, 2208-2219.	13.9	696
13	Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction. Circulation, 2003, 107, 1486-1491.	1.6	652
14	C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study. Circulation, 2004, 110, 380-385.	1.6	594
15	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nature Genetics, 2018, 50, 1514-1523.	9.4	497
16	Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women. JAMA - Journal of the American Medical Association, 2007, 298, 776.	3.8	496
17	Association of Cholesteryl Ester Transfer Protein– <i>Taq</i> IB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1323-1329.	1.1	385
18	LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. Journal of Clinical Lipidology, 2007, 1, 583-592.	0.6	365

#	Article	IF	CITATIONS
19	Apolipoprotein E Alleles, Dyslipidemia, and Coronary Heart Disease. JAMA - Journal of the American Medical Association, 1994, 272, 1666.	3.8	323
20	Impact of Body Mass Index on Coronary Heart Disease Risk Factors in Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1509-1515.	1.1	284
21	Cumulative Effects of High Cholesterol Levels, High Blood Pressure, and Cigarette Smoking on Carotid Stenosis. New England Journal of Medicine, 1997, 337, 516-522.	13.9	277
22	Intake of Dietary Phytoestrogens Is Low in Postmenopausal Women in the United States: The Framingham Study. Journal of Nutrition, 2001, 131, 1826-1832.	1.3	271
23	Diabetes Mellitus–Related Allâ€Cause and Cardiovascular Mortality in a National Cohort of Adults. Journal of the American Heart Association, 2019, 8, e011295.	1.6	271
24	Sex and Age Differences in Lipoprotein Subclasses Measured by Nuclear Magnetic Resonance Spectroscopy: The Framingham Study. Clinical Chemistry, 2004, 50, 1189-1200.	1.5	259
25	Associations of Adiponectin, Resistin, and Tumor Necrosis Factor-α with Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3165-3172.	1.8	229
26	Association Between Increased Estrogen Status and Increased Fibrinolytic Potential in the Framingham Offspring Study. Circulation, 1995, 91, 1952-1958.	1.6	229
27	Differences in Low Density Lipoprotein Subfractions and Apolipoproteins in Premenopausal and Postmenopausal Women*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 30-35.	1.8	228
28	Impact of Insulin Resistance on Risk of Type 2 Diabetes and Cardiovascular Disease in People With Metabolic Syndrome. Diabetes Care, 2007, 30, 1219-1225.	4.3	224
29	Association of C-Reactive Protein With Carotid Atherosclerosis in Men and Women: The Framingham Heart Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1662-1667.	1.1	217
30	Alcohol Consumption and Hemostatic Factors. Circulation, 2001, 104, 1367-1373.	1.6	211
31	Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nature Medicine, 2019, 25, 1274-1279.	15.2	177
32	LEISURE TIME PHYSICAL ACTIVITY IN THE FRAMINGHAM OFFSPRING STUDY. American Journal of Epidemiology, 1989, 129, 76-88.	1.6	176
33	Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. American Journal of Clinical Nutrition, 2002, 75, 38-46.	2.2	172
34	Association of Blood Pressure With Fibrinolytic Potential in the Framingham Offspring Population. Circulation, 2000, 101, 264-269.	1.6	167
35	Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism: Clinical and Experimental, 1996, 45, 1267-1272.	1.5	154
36	Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nature Genetics, 2019, 51, 1574-1579.	9.4	152

#	Article	IF	CITATIONS
37	Race and Socioeconomic Status Independently Affect Risk of Major Amputation in Peripheral Artery Disease. Journal of the American Heart Association, 2018, 7, .	1.6	139
38	Prediction of First Events of Coronary Heart Disease and Stroke With Consideration of Adiposity. Circulation, 2008, 118, 124-130.	1.6	138
39	Antecedent Blood Pressure and Risk of Cardiovascular Disease. Circulation, 2002, 105, 48-53.	1.6	136
40	Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. American Journal of Clinical Nutrition, 2001, 73, 638-646.	2.2	128
41	Folic Acid Fortification Increases Red Blood Cell Folate Concentrations in the Framingham Study. Journal of Nutrition, 2001, 131, 3277-3280.	1.3	116
42	The NHLBI Twin Study: heritability of apolipoprotein A-I, B, and low density lipoprotein subclasses and concordance for lipoprotein(a). Atherosclerosis, 1991, 91, 97-106.	0.4	115
43	Lifetime Risk of Coronary Heart Disease by Cholesterol Levels at Selected Ages. Archives of Internal Medicine, 2003, 163, 1966.	4.3	112
44	Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking. Hypertension, 2003, 42, 1100-1105.	1.3	104
45	Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample The Framingham offspring study. Atherosclerosis, 1987, 68, 59-66.	0.4	96
46	Evidence of Systemic Inflammation and Estimation of Coronary Artery Disease Risk: A Population Perspective. American Journal of Medicine, 2008, 121, S15-S20.	0.6	78
47	Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program. Circulation, 2020, 142, 1633-1646.	1.6	78
48	Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy. JAMA Cardiology, 2018, 3, 849.	3.0	75
49	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. Journal of Clinical Lipidology, 2021, 15, 629-648.	0.6	69
50	Cardiometabolic risk: a Framingham perspective. International Journal of Obesity, 2008, 32, S17-S20.	1.6	60
51	High‣ensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Longâ€∓erm Outcomes. Journal of the American Heart Association, 2018, 7, .	1.6	57
52	Differences in apolipoproteins and low-density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: Results from the Framingham Offspring Study. Metabolism: Clinical and Experimental, 1990, 39, 1033-1038.	1.5	54
53	Use of Alternative Thresholds Defining Insulin Resistance to Predict Incident Type 2 Diabetes Mellitus and Cardiovascular Disease. Circulation, 2008, 117, 1003-1009.	1.6	53
54	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	40

#	Article	IF	CITATIONS
55	Estimation of Atherosclerotic Cardiovascular Disease Risk Among Patients in the Veterans Affairs Health Care System. JAMA Network Open, 2020, 3, e208236.	2.8	23
56	Antecedent blood pressure as a predictor of cardiovascular disease. Journal of the American Society of Hypertension, 2015, 9, 690-696.e1.	2.3	20
57	A phenotyping algorithm to identify acute ischemic stroke accurately from a national biobank: the Million Veteran Program. Clinical Epidemiology, 2018, Volume 10, 1509-1521.	1.5	20
58	Risk-factor profile, drug usage and cardiovascular events within a year in patients with and at high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asian regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry. Heart Asia, 2011, 3, 93-8.	1.1	19
59	A Message from the Laboratory Community to the National Cholesterol Education Program Adult Treatment Panel IV. Clinical Chemistry, 2012, 58, 523-527.	1.5	18
60	Interaction between diabetes and a high ankle–brachial index on mortality risk. European Journal of Preventive Cardiology, 2015, 22, 615-621.	0.8	18
61	Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. European Journal of Preventive Cardiology, 2014, 21, 1531-1540.	0.8	17
62	Mendelian Randomization Analysis of Hemostatic Factors and Their Contribution to Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 41, 380-386.	1.1	14
63	Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extendedâ€Release Niacin in Hyperlipidemic Patients. Journal of the American Heart Association, 2013, 2, e000037.	1.6	13
64	Yield and bias in defining a cohort study baseline from electronic health record data. Journal of Biomedical Informatics, 2018, 78, 54-59.	2.5	13
65	A multi-population phenome-wide association study of genetically-predicted height in the Million Veteran Program. PLoS Genetics, 2022, 18, e1010193.	1.5	12
66	Comparison of the Association Between High-Sensitivity Troponin I and Adverse Cardiovascular Outcomes in Patients With Versus Without Chronic Kidney Disease. American Journal of Cardiology, 2018, 121, 1461-1466.	0.7	11
67	Lipids and Vascular Disease: A Framingham Perspective. Global Heart, 2013, 8, 25.	0.9	11
68	Baseline Levels, and Changes Over Time in Body Mass Index and Fasting Insulin, and Their Relationship to Change in Metabolic Trait Clustering. Metabolic Syndrome and Related Disorders, 2014, 12, 372-380.	0.5	9
69	Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 2021, , .	1.4	9
70	Lipids, Lipases, and Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1854-1856.	1.1	8
71	Type 2 diabetes risk in persons with dysglycemia: The Framingham Offspring Study. Diabetes Research and Clinical Practice, 2011, 92, 124-127.	1.1	8
72	Racial and Ethnic Differences in Short- and Long-term Mortality by Stroke Type. Neurology, 0, , 10.1212/WNL.000000000200575.	1.5	7

#	Article	IF	CITATIONS
73	Risk of type 2 diabetes mellitus and coronary heart disease: a pivotal role for metabolic factors. Country Review Ukraine, 2008, 10, B11-B15.	0.8	6
74	Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Clinically Observed Longitudinal Cholesterol Exposure. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003501.	1.6	6
75	Association Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With Diabetes. Diabetes Care, 2019, 42, 1995-2003.	4.3	5
76	Changing Cholesterol Levels and Coronary Heart Disease Risk. Circulation, 2016, 133, 239-241.	1.6	4
77	Lipoprotein measurements—setting priorities11Am J Med. 2001;110:71–72 American Journal of Medicine, 2001, 110, 71-72.	0.6	3
78	Low Blood Pressure, Comorbidities, and Ischemic Stroke Mortality in US Veterans. Stroke, 2022, 53, 886-894.	1.0	3
79	Highlights in ASCVD Primary Prevention forÂ2021. Journal of the American Heart Association, 2022, 11, .	1.6	3
80	Impact of Dietary Intake on Bone Turnover in Patients with Phenylalanine Hydroxylase Deficiency. JIMD Reports, 2017, 36, 67-77.	0.7	2
81	Optimizing Atherosclerotic Cardiovascular Disease Risk Estimation for Veterans With Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, CIRCOUTCOMES120006528.	0.9	2
82	Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. Hypertension, 2021, 78, 376-386.	1.3	2
83	Genome-wide and phenome-wide analysis of ideal cardiovascular health in the VA Million Veteran Program. PLoS ONE, 2022, 17, e0267900.	1.1	2
84	Diabetes Mellitus and Control of Cardiovascular Disease Risk Factors. Circulation, 2017, 136, 1204-1206.	1.6	1
85	Risk assessment with newer statistical metrics. Statistics in Medicine, 2017, 36, 4509-4510.	0.8	1
86	Circulating progenitor cells in patients with familial hypercholesterolemia. Journal of Clinical Apheresis, 2018, 33, 404-408.	0.7	1
87	Homocysteine: The New Risk Factor for Cardiovascular Disease in the Elderly. The American Journal of Geriatric Cardiology, 2000, 9, 185-189.	0.7	Ο
88	Response to Letter Regarding Article, "Use of Alternative Thresholds Defining Insulin Resistance to Predict Incident Type 2 Diabetes Mellitus and Cardiovascular Disease― Circulation, 2008, 118, .	1.6	0
89	No One Size Fits All. Journal of the American College of Cardiology, 2016, 68, 636-638.	1.2	0
90	Development and Progression of CoronaryÂArtery Calcification. JACC: Cardiovascular Imaging, 2017, 10, 867-868.	2.3	0